Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891006721> ?p ?o ?g. }
Showing items 1 to 56 of
56
with 100 items per page.
- W2891006721 abstract "3569 Background: Debate exists as to whether first line bevacizumab effects subsequent sensitivity to anti-EGFR therapy. Authors hypothesize that initial anti-VEGF therapy may induce biological changes that then increase the risk of acquired resistance to subsequent EGFR inhibitors. Methods: A retrospective cohort study was performed to compare the characteristics and survival of patients who were treated with an anti-EGFR therapy 2nd line and beyond by two groups defined by the first line therapy; 1. chemotherapy (chemo) plus bevacizumab (bev) and 2. chemo alone. Survival for this analysis is from the time of commencing first line chemotherapy and secondly from anti-EGFR therapy. Pearson chi test analysis was performed to determine whether receiving first line bev was associated with worse overall survival (OS). Results: 348 mCRC patients who received chemo with or without bev and then an anti-EGFR therapy were studied. Patient characteristics are summarised in the table below. The significant differences between group 1. Vs. 2. were as follows; median age 63.8 years v 67.9 years (p = 0.005), lower use of single agent FU 6.4% v 19.2%, KRAS status not tested (reflecting the practice changes over time) 19.3% v 39.2%, KRAS MT 2% v 4%, and where BRAF MT status was known (11%); BRAF MT rate 23% v 0. Median OS for the 2 groups was 34.2 months, and 28.2 months respectively (p = 0.12) from first line therapy. Median OS for patients who underwent single agent anti-EGFR as subsequent therapy was also not significantly different, 31.1 months group 1 (n = 60) versus 27.7 months group 2 (n = 85), p = 0.52. Results based on commencement of anti-EGFR therapy are under way. Conclusions: Survival was not significantly different between the two groups, and the trend was towards higher OS with chemo plus bev suggesting that in our registry population, bev administration in first line therapy with chemo did not lead to a worse outcome overall for those patients subsequently receiving anti-EGFR therapy, either with chemotherapy or as a single agent. Updated results from commencement of anti-EGFR therapy will give further insights and will be presented at the meeting." @default.
- W2891006721 created "2018-09-27" @default.
- W2891006721 creator A5009918504 @default.
- W2891006721 creator A5015610217 @default.
- W2891006721 creator A5034008035 @default.
- W2891006721 creator A5048682770 @default.
- W2891006721 creator A5053664013 @default.
- W2891006721 creator A5058363506 @default.
- W2891006721 creator A5058526313 @default.
- W2891006721 creator A5061460550 @default.
- W2891006721 creator A5070238121 @default.
- W2891006721 date "2017-05-20" @default.
- W2891006721 modified "2023-09-27" @default.
- W2891006721 title "Bevacizumab and its impact on survival for patients receiving subsequent anti-EGFR therapy: Updated results from the SA metastatic CRC registry." @default.
- W2891006721 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.3569" @default.
- W2891006721 hasPublicationYear "2017" @default.
- W2891006721 type Work @default.
- W2891006721 sameAs 2891006721 @default.
- W2891006721 citedByCount "0" @default.
- W2891006721 crossrefType "journal-article" @default.
- W2891006721 hasAuthorship W2891006721A5009918504 @default.
- W2891006721 hasAuthorship W2891006721A5015610217 @default.
- W2891006721 hasAuthorship W2891006721A5034008035 @default.
- W2891006721 hasAuthorship W2891006721A5048682770 @default.
- W2891006721 hasAuthorship W2891006721A5053664013 @default.
- W2891006721 hasAuthorship W2891006721A5058363506 @default.
- W2891006721 hasAuthorship W2891006721A5058526313 @default.
- W2891006721 hasAuthorship W2891006721A5061460550 @default.
- W2891006721 hasAuthorship W2891006721A5070238121 @default.
- W2891006721 hasConcept C121608353 @default.
- W2891006721 hasConcept C126322002 @default.
- W2891006721 hasConcept C143998085 @default.
- W2891006721 hasConcept C2776694085 @default.
- W2891006721 hasConcept C2777802072 @default.
- W2891006721 hasConcept C2778527826 @default.
- W2891006721 hasConcept C2781230642 @default.
- W2891006721 hasConcept C2992356464 @default.
- W2891006721 hasConcept C3019894029 @default.
- W2891006721 hasConcept C71924100 @default.
- W2891006721 hasConceptScore W2891006721C121608353 @default.
- W2891006721 hasConceptScore W2891006721C126322002 @default.
- W2891006721 hasConceptScore W2891006721C143998085 @default.
- W2891006721 hasConceptScore W2891006721C2776694085 @default.
- W2891006721 hasConceptScore W2891006721C2777802072 @default.
- W2891006721 hasConceptScore W2891006721C2778527826 @default.
- W2891006721 hasConceptScore W2891006721C2781230642 @default.
- W2891006721 hasConceptScore W2891006721C2992356464 @default.
- W2891006721 hasConceptScore W2891006721C3019894029 @default.
- W2891006721 hasConceptScore W2891006721C71924100 @default.
- W2891006721 hasLocation W28910067211 @default.
- W2891006721 hasOpenAccess W2891006721 @default.
- W2891006721 hasPrimaryLocation W28910067211 @default.
- W2891006721 isParatext "false" @default.
- W2891006721 isRetracted "false" @default.
- W2891006721 magId "2891006721" @default.
- W2891006721 workType "article" @default.